Long-Term Benefits of Composite Treatment Targe...

By HEOR Staff Writer

January 21, 2026

Sustained Composite Treatment Targets Enhance Clinical and Economic Outcomes in Type 2 Diabetes A recent modeling study examines the lon...
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...